Axsome Therapeutics, Inc (AXSM) is a publicly traded Healthcare sector company. As of July 7, 2026, AXSM trades at $243.81 with a market cap of $12.57B and a P/E ratio of -64.74. AXSM moved -0.67% today. Year to date, AXSM is +63.05%; over the trailing twelve months it is +130.08%. Its 52-week range spans $75.56 to $260.19. Analyst consensus is strong buy with an average price target of $266.69. Rallies surfaces AXSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Axsome Begins Phase 3 ADHD Trial in 468 Children with Solriamfetol: Axsome Therapeutics has dosed the first patient in FOCUS-2, a Phase 3 trial evaluating solriamfetol in 468 children aged 6 to <12 with ADHD. Patients are randomized 1:1:1 to two solriamfetol doses or placebo for six weeks, with ADHD-RS-5 score change as the primary endpoint.
| Metric | Value |
|---|---|
| Price | $243.81 |
| Market Cap | $12.57B |
| P/E Ratio | -64.74 |
| EPS | $-3.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $260.19 |
| 52-Week Low | $75.56 |
| Volume | 49.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $708.24M |
| Net Income | $-188.30M |
| Gross Margin | 0.00% |
17 analysts cover AXSM: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $266.69.